Medical Imaging Industry Market Research Report 2026–2031

1. Executive Summary

1a. Synthesis Overview

The global medical imaging market enters 2026 valued at roughly $45.5 billion to $48.6 billion, depending on which research house you accept and where they draw the boundary of the sector. Grand View Research puts 2026 at $45.5 billion, Fortune Business Insights at $46.9 billion, and The Business Research Company at $48.63 billion. Published growth rates cluster between 4.7% and 6.7% through the early 2030s. Applied to a 2026 midpoint of roughly $47 billion, that consensus points to a global market near $62 billion by 2031.

That headline number is accurate and, on its own, misleading. The imaging hardware base compounds at mid single digits. The layers wrapped around that hardware do not. Contrast media is growing at roughly 7.8% to 8.4% a year. Refurbished imaging systems are growing at high single to low double digits. Imaging equipment services and maintenance are compounding above 6%. Photon-counting CT is compounding at 25% to 30% off a small base. Radiology AI, depending on definitional scope, is compounding somewhere between 24% and 38%. The scanner is becoming the least interesting part of the scanner business.

Three forces set the 2026 to 2031 trajectory, and they pull against each other. Demand is structurally locked in and cannot be legislated away: aging populations, chronic disease burden, and expanding screening programs push imaging volumes up roughly 3% to 4% annually, while the radiologist workforce is capped by residency funding and cannot absorb it. Reimbursement is moving in the opposite direction: CMS finalized a 2.5% efficiency adjustment for CY 2026 that cuts work RVUs across most diagnostic imaging, with an estimated net impact of -2% for diagnostic radiology. And trade policy has shifted from a shock to a permanent planning variable, with a Section 232 national security investigation covering imaging machines running to a target completion date of July 24, 2026.

The result is a sector where volume rises, unit price falls, capital budgets tighten, and margin migrates toward recurring revenue. Every strategically significant move by the incumbents in the last eighteen months has been an attempt to get in front of exactly that.

1b. Headline Findings

• Current market size. Global medical imaging is estimated at $45.5 billion to $48.6 billion in 2026 (Grand View Research, Fortune Business Insights, The Business Research Company, Global Market Insights). North America held the largest regional share at 36.3% in 2025, per Grand View Research.
• Projected market size. A base case of roughly $62 billion by 2031, with a defensible band of $56 billion to $67 billion depending on tariff outcomes, reimbursement severity, and capital replacement timing.
• Concentration is extreme. Global Market Insights estimates GE HealthCare alone held over 32% share in 2025, and that the top five (GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm) collectively held roughly 90%. That is an oligopoly, not a market.
• The workforce gap is the sector's engine. The Harvey L. Neiman Health Policy Institute projects the US radiologist workforce growing 25.7% between 2023 and 2055 against imaging demand growth of 16.9% to 26.9%, meaning the present shortage neither worsens nor resolves without intervention. AuntMinnie named radiology workforce shortages the specialty's biggest threat for three consecutive years through 2025.
• AI has cleared the regulator but not the payer. The FDA has authorized 1,524 AI-enabled devices as of March 30, 2026, of which 1,163 are radiology, or 76.31% of all AI clearances. Yet cardiac imaging AI remains the only radiology AI category with dedicated Category I CPT reimbursement codes, and by one analysis, only about 2.4% of cleared AI devices have been validated through a randomized controlled trial.
• Value is moving to the aftermarket. GE HealthCare paid $2.3 billion for Intelerad, closing March 18, 2026, explicitly to buy recurring software revenue (about $270 million in year one, roughly 90% recurring) and an outpatient footprint. Refurbished systems sell at 40% to 60% below new. Medical imaging equipment services is a market Research Nester sizes at $22.84 billion in 2026.

1c. Directional Verdict

Moderate, durable growth in the core, with high-growth pockets at the edges. This is not a boom sector, and it is not a declining one. Between 2026 and 2031, the global medical imaging market should compound in the mid single digits to roughly $62 billion, underpinned by demand that is demographically guaranteed. But growth in the installed base of new capital equipment will be the slowest-moving part of the sector. The compounding is in software, service, consumables, and refurbishment. Companies whose revenue is tied to selling a box will fight for a share in a 5% market. Companies whose revenue is tied to keeping that box running, feeding it, replacing it affordably, or reading its output faster will operate in markets growing two to six times as fast.

2. Present-Day Sector Overview

2a. Sector Definition & Scope

This report treats "medical imaging" as the full commercial ecosystem around diagnostic visualization, not merely the scanner manufacturers. That distinction matters because the published market-size figures that differ most sharply differ precisely because of where they draw this line.

The sector comprises five distinct layers, each with its own economics:

• Capital equipment. X-ray and digital radiography, computed tomography, magnetic resonance imaging, ultrasound, nuclear and molecular imaging (PET, SPECT), mammography, and interventional or surgical systems, including C-arms. Global Market Insights valued the X-ray devices segment alone at $14.1 billion in 2025. Grand View Research reports MRI as the largest technology segment at 27.9% of 2025 revenue, with CT the fastest growing.
• Consumables and contrast. Iodinated and gadolinium-based contrast agents, microbubble agents, power injectors, syringes and tubing, film and dry laser film, and the radiology department supply chain. Mordor Intelligence sizes global contrast media at $6.99 billion in 2026; MarketsandMarkets puts it higher at $8.20 billion.
• Software and informatics. PACS, RIS, enterprise imaging, cloud viewers, and the rapidly expanding AI layer for triage, detection, reconstruction, and reporting.
• Aftermarket. Service and maintenance contracts, parts, refurbished systems, equipment relocation and removal, room planning and design, radiation shielding, and applications training. Research Nester sizes the global medical imaging equipment services at $22.84 billion in 2026.
• Delivery. The provider layer that consumes all of the above. Grand View Research sizes US imaging services at $104.25 billion in 2025, growing at only 1.9% through 2033, with fixed radiology services at 93.5% of revenue and hospitals at 58.2%. That near-flat services growth against mid-single-digit equipment growth is one of the most important tensions in the sector.

2b. Market Size & Current Growth

Market-sizing in medical imaging varies widely between firms, and most detailed figures sit behind paywalls. The honest presentation is a range with each figure attributed.

The MarketsandMarkets figure is not an outlier so much as a different question: it measures "diagnostic imaging" on a narrower modality definition. Read across the five comparable estimates, and 2026 sits in a $45.5 billion to $48.6 billion band with a consensus growth rate of roughly 5% to 6.5%.

The primary reference for the sizing used throughout this report is Grand View Research's medical imaging market analysis, cross-checked against Fortune Business Insights, Global Market Insights, and The Business Research Company. Where those sources conflict, this report presents the range rather than a single point.

[IMAGE SUGGESTION: Column chart of global medical imaging market size, 2026 through 2031, plotting the $45.5B-$48.6B 2026 band against the $56B / $62B / $67B bear-base-bull 2031 outcomes. Source: Section 2b table and Section 4a scenario table.]

2c. Demand Drivers

• Demographics. The United Nations Population Division anticipates the population aged 65 and above doubling to 1.6 billion by 2050. Grand View Research identifies this as the single most consistent driver of imaging demand, because aging correlates directly with the conditions that require diagnostic visualization: cardiovascular disease, stroke, cancer, and osteoporosis.
• Chronic disease burden. The WHO attributes 17.9 million annual deaths to cardiovascular disease and nearly 10 million to cancer. Market Research Future cites WHO estimates of more than 3.6 billion diagnostic imaging procedures performed annually worldwide.
• Volume growth outpacing workforce. Imaging volumes are rising roughly 3% to 4% a year. The Neiman Institute found radiologists left the workforce at a 50% higher rate starting in 2020, and that the number of medical practices with affiliated radiologists fell 14.7% from 2014 to 2023, even as radiologist headcount rose 17.3%, pushing average practice size from 9.7 to 17.9 radiologists.
• The outpatient shift. Fortune Business Insights projects diagnostic imaging centers at 47.08% of the market by end-use in 2026, and Grand View Research identifies diagnostic imaging centers as the fastest-growing end-use segment. HealthCare Appraisers counted more than 6,000 independent diagnostic testing facilities in the US.
• Screening expansion. Lung cancer screening, contrast-enhanced mammography (India's CDSCO approved Bayer's Ultravist for CEM in February 2026; the FDA approved it in the US in 2023), and cardiac CT angiography all add scan volume per capita rather than merely redistributing it.
• Emerging market build-out. Low installed-system density outside North America and Western Europe is the largest untapped pool of demand in the sector, and it is being served disproportionately by refurbished equipment and lower-cost entrants.

2d. Value Chain & Business Models

Understanding where money is made in imaging requires separating five business models that are often conflated:

• OEM direct. The top five manufacturers sell capital systems and increasingly bundle multi-year service contracts, software subscriptions, and applications training into a single turnkey agreement. Signify Research notes OEMs are deliberately transitioning into turnkey solution providers to secure predictable recurring income.
• Distribution and dealer channel. Independent distributors aggregate multiple manufacturers, hold local inventory, and sell into facilities too small for OEM direct coverage. Their margin lives in consumables velocity, private label, and service attach rather than in hardware markup.
• Independent service organizations. ISOs compete with OEM service contracts on price, typically at 30% to 40% below OEM rates. Grand View Research notes that the small and third-party provider segment is expected to be the fastest-growing part of the medical equipment maintenance market, while OEMs remain the largest.
• Refurbishers. Refurbished imaging equipment sells at 40% to 60% below new, according to Verified Market Research. All three top OEMs now run their own certified refurbishment programs, which is both validation of the model and a competitive threat to independent refurbishers.
• Contrast and consumables pharma. Bayer, Bracco, Guerbet, GE HealthCare, and Lantheus dominate contrast media. Mordor Intelligence notes iodinated agents held 71.52% of the contrast market in 2025, and that iodine sourcing dependence on Chile and Japan creates real price and supply risk.

2e. Headwinds & Constraints

3. Competitive Landscape

3a. Market Leaders

Medical imaging is one of the most concentrated markets in healthcare. Global Market Insights estimates the top five manufacturers held roughly 90% of the market in 2025, with GE HealthCare alone above 32%. The FDA's AI clearance list gives an independent read on the same hierarchy: GE HealthCare leads all companies with 120 radiology AI authorizations, followed by Siemens Healthineers at 89, Philips at 50, Canon at 45, and United Imaging at 38.

[IMAGE SUGGESTION: Competitive positioning bubble chart plotting the eight leaders on estimated market share (x-axis) against FDA radiology AI authorization count (y-axis), bubble size = breadth of modality coverage. Source: Global Market Insights share estimates and the FDA AI-enabled device list as of March 30, 2026, both cited in Section 3a.]

3b. Emerging Challengers & Disruptors

No startup is going to out-manufacture Siemens on a CT gantry. The challengers are attacking the layers where capital intensity is low, and the incumbents are slow.

• Aidoc (Tel Aviv and New York). The most-deployed pure-play radiology AI vendor, with more than 31 FDA-cleared tools running across nearly 2,000 hospitals and processing roughly 60 million patient cases annually. In January 2026, it received clearance for the first foundation-model-powered clinical AI device: a single-body CT triage solution covering 14 conditions with a mean sensitivity of 97% and specificity of 98% in its pivotal study. It raised a $150 million Series E in April 2026, led by Goldman Sachs, with Nvidia's NVentures participating, taking total funding past $500 million.
• Viz.ai. Focused on time-critical conditions where minutes change outcomes. Its large vessel occlusion stroke detection from CT angiography, with real-time smartphone alerts to stroke teams, is deployed at more than 1,700 hospitals across 50-plus cleared algorithms. Stroke and vascular triage is where the AI clinical evidence base is strongest.
• DeepHealth (RadNet). Twenty-eight FDA authorizations, including the Quantib and iCAD acquisitions. The strategic point is the ownership structure: a provider network that owns its own AI vendor is a different animal from an imaging chain that licenses one.
• Hyperfine. Its FDA-cleared Swoop portable ultra-low-field MRI uses NVIDIA AI for image quality and installs in a footprint the size of a ventilator cart. Mordor Intelligence projects portable MRI as the fastest-growing US MRI format at 6.31% CAGR through 2031. This is the classic disruption geometry: a workflow the incumbents find difficult to replicate without cannibalizing flagship products.
• Cautionary counterexample: Nanox Imaging. The company has warned of "going concern" risk as losses deepen. Novel imaging hardware is a graveyard, and the record supports it: capital intensity and regulatory burden punish undercapitalized entrants.
• Adjacent entrant: Midjourney Medical. In June 2026, the AI image-generation company announced a whole-body ultrasound scanner with 358,000 sensors, processing roughly 40 GB per slice across 21 servers to produce a 3D cross-section in about 60 seconds, backed by more than $74 million in investment. It has no FDA diagnostic clearance. Whether it succeeds matters less than what it signals: consumer-technology capital now considers imaging hardware an addressable market.

3b.1 Company Spotlight: Spectrum Medical X-Ray Company

Spectrum Medical X-Ray Company, also operating as Spectrum Medical Imaging Co., is a Santa Monica, California-headquartered independent distributor and service organization serving the diagnostic imaging market nationwide. It has served the medical imaging community for more than four decades. Unlike every company profiled in Section 3a, Spectrum does not manufacture. It occupies the layer between the OEMs and the facility, and that position is the whole analysis.

What they do. Spectrum runs a single-source model across the full imaging lifecycle: new and refurbished equipment sales, installation, relocation, transport and storage, room planning and design, radiation shielding, applications training, and field service delivered by factory-trained engineers covering general radiography, C-arms, and Guerbet, Medrad, and Bracco injectors. Alongside equipment, the company distributes X-ray and dry laser film, a full line of iodinated and gadolinium contrast media, and radiology department supplies, reporting service to over 400 imaging centers nationwide. It is an authorized distributor for Carestream, Agfa, Sony, Konica Minolta, FujiFilm, Bracco, Mallinckrodt, EZ-EM, GE, and Bayer, among others, and it holds a supplier position with the MAGNET GROUP purchasing organization. It also sells Spectravue, its own branded syringes and tubing compatible with certain OEM injector models from Guerbet, Bracco, and Medrad.

The sub-segment they play in. Spectrum sits at the intersection of the three fastest-compounding layers identified in Section 4d: consumables and contrast (roughly 7.8% to 8.4% CAGR), refurbished imaging equipment (high single to low double digits), and imaging equipment services (roughly 6.2%). It is deliberately absent from the layer growing slowest, which is new capital hardware manufacture, and absent from the layer growing fastest, which is proprietary imaging software and AI. That is a coherent position, not an accidental one.

Differentiation and moat. Three things are genuinely defensible. First, multi-vendor independence: an OEM cannot credibly tell a customer that the competitor's injector is the right answer, and Spectrum can. Second, the consumables annuity: contrast, film, and syringes recur whether or not the facility has a capital budget this year, and the company backs this with 24 to 48-hour nationwide delivery and a stated willingness to beat competitor pricing. Third, service depth on the specific equipment that its customers actually run, with factory-trained engineers on injector brands that dominate the installed base. The Spectravue private label is the highest-margin expression of all three, converting a distribution relationship into a product one.

Honest read on competitive position. Spectrum is not a market leader and should not be positioned as one. It is a durable, regionally headquartered, independent with national reach, competing in a channel that the OEMs are actively trying to compress. Four pressures are real. GE HealthCare's $2.3 billion Intelerad purchase and the broader turnkey bundling trend that Signify Research documents are explicitly designed to pull service, software, and equipment into a single OEM contract, which squeezes independents out of the conversation. Buyer consolidation works in the same direction: RadNet operates 350-plus centers on more than $2 billion in trailing revenue, and SimonMed roughly 170 sites, and platforms at that scale negotiate national contracts that favor scale suppliers. The legacy film and dry laser film line, historically a strength, is in secular decline. And Spectrum has no proprietary software or AI layer, which is where the sector's fastest value creation is happening.

Why are they positioned to win anyway? The countervailing case is strong, and it rests on where the sector is actually going. Capital budgets are tightening under a -2% CMS impact on diagnostic radiology while volumes rise 3% to 4% a year. Facilities in that squeeze do not buy new flagship scanners; they extend the life of what they own, buy refurbished at 40% to 60% below new, cut OEM service costs by 30% to 40% by moving to independents, and keep the consumables flowing. Every one of those behaviors routes to Spectrum's model. The independent diagnostic testing facility and specialty clinic segments, where Spectrum competes best because OEM direct coverage is thin, are the fastest-growing end-use segments in the market. Spectrum's brand position as the experienced partner is not marketing decoration here; in a market where the buyer's pain is unplanned downtime and unpredictable capital expenditure, reliability and single-source simplicity are the product.

What they must do. Shift revenue mix decisively from analog consumables toward service contracts, refurbished capital, and private-label injector consumables. Attach to the ambulatory build-out rather than defending hospital accounts against OEM turnkey bids. And find a defensible answer on the software layer, whether through partnership or integration services, because a distributor with no position in the AI-era refresh cycle will eventually be selling only the parts of the room that do not think.

3c. Competitive Intensity: Porter's Five Forces

4. Forward Outlook: 2026 to 2031

4a. Market Size Projections: Bull, Base, Bear

The scenarios below apply the published CAGR range to the published 2026 size range. They are reasoned projections built on named sources, not independently modelled forecasts, and they should be read as a band rather than a point.

[IMAGE SUGGESTION: Grouped column chart comparing bull/base / bear global market size at 2031 ($67B / $62B / $56B) against the 2026 baseline, with CAGR labelled on each column. Source: Section 4a table.]

4b. Structural Shifts to Expect

• From box to subscription. GE HealthCare's stated rationale for Intelerad was explicit: accelerate growth in SaaS products and recurring revenues as it evolves from a device maker into a solutions provider. Intelerad is expected to contribute roughly $270 million in first-year revenue with about 90% recurring, across more than 1,500 healthcare organizations. Every major OEM is running some version of this play.
• From hospital to ambulatory. Intelerad's value to GE was its outpatient footprint precisely because GE was strong in hospitals and weak outside them. RadNet added Radiology Regional and its 13 centers for roughly $100 million in annual revenue, entered the Midwest through Northwest Radiology, and closed Chesapeake Medical Imaging in March 2026. Imaging center transaction multiples now run from 4x-6x EBITDA for a single site up to 9x-12x+ for a premium multi-state platform.
• From new to refurbished. Towards Healthcare reports medical imaging systems accounted for 60% of the refurbished medical equipment market in 2025, and Persistence Market Research puts imaging at 39.6% of refurbished revenue in 2026 on a broader definition. The direction is not in dispute, even if the sizing is: North American hospitals reported roughly 30% annual savings from integrating refurbished imaging systems.
• From algorithm to platform. The FDA is now clearing roughly 30 AI devices a month, up from 21 a month in 2024. With 1,163 cleared radiology algorithms, no department can integrate them one at a time. The winners will be the orchestration layers, which is why Konica Minolta partnered with deepc in January 2026 to connect a radiology AI operating system to the Exa Platform, and why GE bought an enterprise imaging platform rather than another algorithm.
• From OEM lock-in to multi-vendor TCO. Signify Research finds third-party maintenance providers gaining traction for mid-range CT and ultrasound once initial OEM contracts expire, and notes procurement decisions increasingly made on total cost of ownership rather than initial price. Right-to-repair legislation will sharpen this divide further.

4c. Technology & Innovation Vectors

4d. Sub-Segment Growth Outlook

This is the most important table in the report. The core equipment market is the slowest-growing segment in its own ecosystem.

[IMAGE SUGGESTION: Horizontal bar chart ranking sub-segments by projected CAGR, from US imaging services delivery at 1.9% through core equipment at 5-6.5%, contrast media at ~8%, refurbished at ~11-15%, theranostics at ~15%, photon-counting CT at ~25-30%, and radiology AI at 24-38%. Source: Section 4d table.]

4e. Regulatory & Policy Outlook

Reimbursement. The CY 2026 Medicare Physician Fee Schedule final rule, issued October 31, 2025, is the most consequential single document in this sector's near-term outlook. For the first time, there are two conversion factors: $33.5675 for qualifying Alternative Payment Model participants (up 3.77%) and $33.4009 for everyone else (up 3.26%). Both include a statutory 2.5% one-year increase from the budget reconciliation act and a 0.49% budget neutrality adjustment. Both are undercut by a finalized -2.5% efficiency adjustment to work RVUs for non-time-based services, which CMS intends to apply every three years with no floor. CMS estimates the net impact at -2% for diagnostic radiology, -1% for nuclear medicine and radiation oncology, and +2% for interventional radiology. The rule also halves indirect practice expense RVUs in the facility setting relative to non-facility, which hits hospital-based radiologists specifically. The full rule is available from

CMS. One genuine positive: the rule makes permanent the virtual direct supervision flexibilities, including for Level 2 contrast administration in physician offices and independent diagnostic testing facilities, provided both audio and video are used.

Appropriate use criteria. The PAMA appropriate use criteria program, which CMS estimated could save $700 million annually, remains paused indefinitely after CMS concluded in the 2024 rule that it could not implement the program as written. The ACR is working with Congress and CMS to remove the real-time claims processing requirement. Until that resolves, there is no systemic brake on imaging volume growth, which is precisely why CMS keeps reaching for per-unit price cuts instead.

Trade policy. The Commerce Department opened a Section 232 national security investigation into medical equipment on September 2, 2025, and disclosed it publicly on September 24, covering imaging machines alongside PPE and consumables. Public hearings ran from May 5 to 8, 2026, with a target completion date of July 24, 2026. In February 2026, the Supreme Court struck down the IEEPA tariffs 6-3, but the administration substituted authority almost immediately under Section 122 of the Trade Act (15% globally, capped at 150 days absent congressional extension) and signalled continued reliance on Section 232. Refund questions on the $134 billion collected through December 14, 2025, are being litigated at the Court of International Trade. AdvaMed is pushing a "zero for zero" reciprocal position, arguing medtech supports roughly 3 million US jobs and exports about $75 billion annually with trade surpluses in most major markets. Not everyone expects the worst: one trade lawyer quoted by MedTech Dive noted the administration does not appear to view medical devices negatively and may instead negotiate relief in exchange for US investment commitments, as it did in the pharmaceutical Section 232 outcome.

Device regulation. The FDA has authorized 1,524 AI-enabled medical devices as of March 30, 2026, of which 1,163 are radiology, or 76.31% of the total; the true imaging share approaches 80% once orthopedic, cardiology, and neurology listings are counted. The agency cleared 295 AI devices in 2025 alone, a single-year record, and is now clearing roughly 30 a month. This August 2025 finalization of Predetermined Change Control Plan guidance gives statutory teeth to pre-approved algorithm updates, which matters more for imaging AI than any other device category because an imaging algorithm is built to keep learning.

4f. Geographic Hotspots

Regional share figures conflict across research houses because they segment the market differently, and the honest reading is to present both.

• North America. Grand View Research puts North America at 36.3% of the global market in 2025, the largest region, driven by the density of industry players and the frequency of new product launches. The US held the largest country-level revenue share. Growth is slow: US imaging services grow at only 1.9% through 2033. This is a replacement and optimization market, not an expansion one.
• Asia-Pacific. The fastest-growing region in essentially every source. Fortune Business Insights goes further and puts Asia-Pacific at 38.98% share in 2025 on its segmentation, ahead of North America, and Business Research Insights concurs at over 40%. United Imaging reported Asia-Pacific revenue up over 40% year on year with record regional revenue. In contrast, media, Mordor projects Asia-Pacific at 9.38% CAGR and MarketsandMarkets at 9.5%, driven by China and India building radiology capacity.
• Europe. Fortune Business Insights sizes Europe at 23.60% of the global market in 2025, generating $10.46 billion and projected at $11.05 billion in 2026. Growth is steady rather than fast, constrained by financial pressure in Germany and Southern Europe, where Signify Research observes hospitals seeking more budget-conscious service solutions.
• MENA and emerging markets. The highest percentage growth in the sector. United Imaging reported emerging market revenue up over 80%, with new orders from Turkey, Kuwait, and Morocco. Fortune Business Insights sizes the GCC market at $1.09 billion in 2025 and Latin America at $2.56 billion, or 5.76% of the global market. These markets are being served disproportionately by refurbished equipment, where Asia-Pacific import volumes rose 22% year on year in 2024.

[IMAGE SUGGESTION: Regional bar chart of projected CAGR by geography (Asia-Pacific, MENA/emerging, Latin America, Europe, North America) with 2025 revenue share shown as a secondary series. Source: Grand View Research and Fortune Business Insights regional figures cited in Section 4f.]

4g. Risk Register

5. Strategic Implications

5a. Where Value Accrues

Follow the acquisitions, because they are more honest than the press releases. GE HealthCare spent $2.3 billion on software with 90% recurring revenue and an outpatient footprint, and $98 million on brain-imaging AI. Philips spent $265 million upfront on vascular imaging with AI. Tempus spent $81.25 million on Paige for seven million digitized pathology slides. Nobody is paying premium multiples for gantries.

Four conclusions follow for anyone allocating capital or effort in this sector between 2026 and 2031:

• Recurring beats transactional. A dollar of service contract or consumable revenue is worth several dollars of one-time hardware revenue, because it survives the capital freeze that fixed reimbursement guarantees will not happen.
• The aftermarket is the growth market. Refurbished systems, multi-vendor service, relocation, and shielding all grow when capital budgets tighten. They are counter-cyclical to the OEM new-equipment cycle, which is precisely why the OEMs are moving into them.
• Consumables are the annuity. Contrast media compounds at nearly 8% regardless of whether a facility buys a scanner this year, and iodinated agents still hold 71.52% of that market. The offsetting risk is real: AI-guided injectors cut per-exam contrast volume by roughly 18%, so unit growth will lag procedure growth.
• The integration layer is contestable. With 1,163 cleared radiology algorithms and roughly 30 more arriving monthly, the scarce capability is not another algorithm. It is whoever can make a heterogeneous fleet of scanners, PACS, and AI tools work together in one department. That is an integration and service competency, not a manufacturing one.

5b. Operating Model & Capability Priorities

• Build a service revenue floor. Multi-vendor field service on the installed base is the most defensible position available to a non-OEM. It is priced 30% to 40% below OEM, it recurs, and it puts an engineer in the building every quarter, which is the cheapest sales channel in existence.
• Treat refurbished as a strategic line, not a discount line. At 40% to 60% below new, refurbished is how a budget-constrained facility says yes. The OEMs know this, which is why GE, Siemens, and Philips all run certified refurbishment programs. Independents win on multi-vendor breadth and speed, not on price alone.
• Own the private label where the margin is. Compatible injector syringes and tubing convert a distribution relationship into a product relationship. Guerbet is the only power injector manufacturer that also produces prefilled contrast syringes, which is exactly the gap a compatible private label exists to fill.
• Hedge the input concentration explicitly. Iodine, helium, and detector components are single-sourced and tariff-exposed. Safety stock, dual sourcing, and correct tariff classification are now core operating capabilities rather than procurement hygiene.
• Get a software answer. Not necessarily a proprietary one. A credible integration, deployment, and validation practice around third-party AI is a legitimate strategic position for a service organization, and it is the one thing that keeps a distributor relevant through the AI-era refresh cycle.

5c. Marketing & Go-To-Market

The buying committee in medical imaging is three people with three different fears, and generic messaging fails because it addresses none of them. This section maps go-to-market to the segments and personas that actually sign.

Segments, in priority order. First, outpatient imaging centers and independent diagnostic testing facilities, because Grand View Research identifies them as the fastest-growing end-use segment, and OEM direct coverage is thin. Second, private practices and specialty clinics (orthopedic, veterinary, chiropractic) needing in-house imaging, where the orthopedics application segment already holds 21.7% of US imaging services revenue, and the buyer has no procurement department to hide behind. Third, hospitals and health systems, which remain 42% of the end-use market per Grand View Research, but where OEM turnkey bundling is strongest and the fight is hardest.

Three personas, three messages:

• The Imaging Director. Fear of unplanned downtime, patient backlog, supply logistics, and untrained staff on new technology. Sells on operational excellence. The proof points that land is guaranteed response times, proactive maintenance programs, 24 to 48 hour supply delivery, and hands-on applications training. Lead with the problem, not the catalogue: minimize downtime, maximize uptime.
• The Administrator (CEO, CFO, clinic owner). Fears unpredictable capital expenditure, multi-vendor complexity, compliance risk, and disruption during upgrades. Sells on predictable value and risk transfer. The proof points are decades of manufacturer relationships translating into pricing leverage, single-source consolidation from equipment through disposal, and expert project management on large-scale upgrades. Quantify it: a refurbished system at 40% to 60% below new, or service at 30% to 40% below OEM, is a board-level number in a year when CMS just took 2% off diagnostic radiology.
• The Lead Technologist. Fears include inconsistent image quality, unreliable equipment, radiation exposure, and workflow friction that eats time with patients. Sells on clinical confidence. The proof points are expertly maintained top-tier equipment, applications training that makes them proficient rather than merely compliant, and comprehensive shielding and safety-compliant solutions. This persona rarely signs the contract and frequently kills it.

Channel and content. Group purchasing organization contracts are the highest-leverage channel for reaching consolidated buyers without competing on national-account terms; a supplier position in a specialty medical GPO focused on capital and small medical equipment is worth more than a dozen cold calls. Content should be educational and problem-led rather than product-led: total cost of ownership modelling, refurbished versus new decision frameworks, injector compatibility guides, and shielding and room planning primers. In a sector where the buyer's dominant emotion is budget anxiety, the vendor who does the math for them wins the meeting.

6. Conclusion & Directional Outlook

6a. What the Evidence Supports

The global medical imaging market will compound in the mid single digits from a $45.5 billion to $48.6 billion base in 2026 to roughly $62 billion by 2031, within a defensible band of $56 billion to $67 billion. Demand is the most reliable variable in the model: an aging population, a chronic disease burden measured in tens of millions of deaths annually, and a radiologist workforce that will not grow fast enough to absorb 3% to 4% annual volume growth. That combination does not reverse inside a five-year window.

The uncertainty is not a demand. It is who captures the value created by that demand, and at what price. CMS has demonstrated with the CY 2026 efficiency adjustment that it will respond to volume growth by cutting per-unit price, and it has scheduled itself to do so every three years with no floor. Trade policy has moved from episodic to structural. And the OEMs, holding roughly 90% of the hardware market between five firms, are spending billions to move into the software, service, and ambulatory layers where the growth actually is.

For anyone in this sector who does not manufacture scanners, the strategic read is unambiguous. The core hardware market is the slowest-growing part of its own ecosystem. Contrast media grows at nearly 8%. Service grows above 6%. Refurbished equipment grows in the double digits. Photon-counting CT and radiology AI grow at multiples of the core. Position against the layers that compound, and against the buyer behaviors that a reimbursement squeeze reliably produces: extend asset life, buy refurbished, cut OEM service cost, keep the consumables flowing.

6b. Recommended Actions

1. Rebalance revenue mix toward recurring layers by 2028. Set an explicit target for the share of revenue coming from service contracts, consumables, and refurbished equipment versus one-time new-hardware transactions. The published growth rates make the case: 6.2% for services and 7.8% to 8.4% for contrast media against 5% to 6.5% for core equipment, and both are insulated from the capital freeze that a -2% CMS impact on diagnostic radiology will produce.
2. Attack the ambulatory segment before the OEMs finish arriving. GE HealthCare paid $2.3 billion for Intelerad specifically to buy an outpatient footprint, which is an admission that the OEMs are weak there and know it. Diagnostic imaging centers are the fastest-growing end-use segment. The window to establish incumbency in that channel is the next 24 months, not the next five years.
3. Build tariff and input volatility into pricing and contracts now. With the Section 232 report targeted for July 24, 2026, and Section 122 authority capped at 150 days, the tariff environment will move again within this planning horizon. Verify classification and valuation, qualify for USMCA where applicable, dual-source iodine-dependent lines, and write price adjustment mechanisms into multi-year contracts rather than absorbing the variance.
4. Take a defensible position on the AI integration layer within 12 months. With 1,163 cleared radiology algorithms and roughly 30 arriving monthly, the scarcity is integration, validation, and deployment, not algorithms. A service organization can own that position through a partnership without building a model. Doing nothing here is the one decision that guarantees irrelevance by 2031.
5. Sell to the fear, not the feature. The Imaging Director fears downtime, the Administrator fears unpredictable capital expenditure, and the Lead Technologist fears image quality and safety. Map every proof point (guaranteed response times, 24 to 48 hour delivery, refurbished at 40% to 60% below new, service at 30% to 40% below OEM, applications training, shielding compliance) to the specific persona whose fear it retires, and lead with the problem rather than the catalogue.